Skip to content
Menu

Citigroup Maintains Buy on Arrowhead Pharmaceuticals, Lowers Price Target to $105

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citigroup analyst Eric Joseph maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $108 to $105.

Citigroup analyst Eric Joseph maintains Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy and lowers the price target from $108 to $105.

Read at benzinga.com